Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Part of paid clinical trials in Seattle, Washington.

Sponsor
All4Cure
Study ID
NCT06149910
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Multiple Myeloma Pathway — OTHER
    Use and adherence to a multiple myeloma pathway.
  • All4Cure Platform — OTHER
    Participant in the All4Cure platform.
  • Documentation Pathway — OTHER
    Use of multiple myeloma pathway through written documentation.

Study Details

All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.

Key Dates

Start date
Apr 18, 2024
Status verified
May 2024
Primary completion
May 31, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Platform
    Patients in this cohort are participating in the All4Cure platform and there has been an established intention to treat according to the clinical pathway. Additionally, the patient's primary physician will also be a participant in the All4Cure platform.
  • Arm: Documentation
    Patients in this cohort are not participating in the All4Cure platform but there has been an established intention to treat according to the clinical pathway.
  • Arm: Off-pathway
    Patients in this cohort are not participating in the All4Cure platform and there has not been in intention to treat according to the clinical pathway that has been established by a landmark time period.

Primary Outcome Measure

To compare rate of tumor response and complete tumor response (≥VGPR and ≥CR) within 12 months of start of front-line therapy between the Documentation and Off-Pathway COHORT groups. [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
All4CureSeattleWashington98126
Jennifer Wren
[email protected]
206-501-8354
Cheng Zheng
[email protected]
619-436-7716

Find similar trials in Seattle, WA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
All4Cure· Seattle, WA

Related Studies